Montreal Centre for Experimental Therapeutics in Cancer
The Montreal Centre for Experimental Therapeutics in Cancer (MCETC) focuses on the development of innovative therapies, drugs, and technologies for the treatment and prevention of cancer.
Originally part of the McGill Centre for Translational Research in Cancer, the MCETC was established in 2000 as a result of a CFI/FRSQ infrastructure award for the construction of a state-of-the-art laboratory to bridge lab and clinical research domains.
The MCETC, located at the Jewish General Hospital, houses a wide range of communal resources, and sponsors core laboratory facilities that support basic and translational research.
Core facilities include:
- clinical research unit;
- cell preparation centre;
- DNA and tissue bank;
- viral vector production unit;
- flow cytometry unit;
- computational biology and drug design unit;
- peptide synthesis laboratory;
- research pathology facility.
The Centre’s research focuses on four main themes:
- molecular target discovery;
- experimental pharmacology, novel therapeutics;
- cell and gene therapy;
- prevention and risk assessment.
The research group
comprises a multidisciplinary and inter-university team
of cancer research experts (basic scientists and
oncologists) from five universities—McGill, Université
de Montréal, Université du Québec à Montréal, Université
Laval, and Université de Sherbrooke)—and six
hospital-based or independent research institutes: the
Lady Davis Institute for Medical Research, l’Institut
National de Recherche Scientifique-Armand Frappier, St.
Justine Hospital Research Centre, Biotechnology Research
Institute of the National Research Council, Centre de
Recherche Clinique et Evaluative du Centre Hospitalier
Universitaire de Québec (CHUQ), and Centre Hospitalier
de l’Université de Sherbrooke.
||Dr. Gerald Batist
(514) 340-8222 x5418